Search

Your search keyword '"Fuchs, Michael"' showing total 1,423 results
Start Over Author "Fuchs, Michael" Publication Type Academic Journals

Refine your results

more »

more »

more »

more »

more »
1,423 results on '"Fuchs, Michael"'

3. The Slow Apocalypse in The Low, Low Woods

Author

Fuchs, Michael and Marini, Anna Marta

Subjects
Appalachia. Coal. Comics. Ecocriticism. Ecogothic. Ecohorror. Extraction. Intersectionality. Mining. Trauma, English literature, PR1-9680
Abstract

The comics series The Low, Low Woods is set in the fictional former coal‑mining town of Shudder‑to‑Think, Pennsylvania. While the mines have long been abandoned, their variegated effects, from poverty to environmental destruction, still haunt the region. This article suggests that The Low, Low Woods identifies a convergence between the exploitation of the natural world, a coal industry on the brink of collapse, and a fragile form of (white) hypermasculinity that promotes a violent and race‑ as well as class‑specific idea of local identity that two teenage, queer women from ethnic minority backgrounds begin to challenge.

Published
2023
Full Text
View/download PDF

5. Deaf awareness workshop for medical students – an evaluation

Author

Kruse, Janina, Zimmermann, Anja, Fuchs, Michael, and Rotzoll, Daisy

Subjects
medical students, deaf awareness, deafness, knowledge, competence, Special aspects of education, LC8-6691, Medicine
Abstract

Background: Due to a lack of communication strategies and knowledge about the Deaf community, health care professionals are often not prepared to provide deaf or hard of hearing patients with accessible and adapted healthcare.Methods: In the present study, a workshop was designed to determine the effect of deaf awareness training on medical students concerning their gain of knowledge regarding deafness and their competence in providing adapted communication and healthcare for deaf and hard of hearing patients. 95 medical students were evaluated in an online survey prior to as well as following the workshop. The workshop was held online in three consecutive sessions.Results: Students reported a substantially more confident approach to working with hearing impaired patients and indicated that an online learning environment is a suitable and helpful alternative to face-to-face teaching. Participants improved significantly in all evaluated items concerning their knowledge and competence (p

Published
2021
Full Text
View/download PDF

6. The Longitudinal Communication Curriculum at Leipzig University, Medical Faculty – implementation and first experiences

Author

Zimmermann, Anja, Baerwald, Christoph, Fuchs, Michael, Girbardt, Christian, Götze, Heide, Hempel, Gunther, von Klitzing, Kai, and Rotzoll, Daisy

Subjects
communication skills, curriculum development, simulated patient, Special aspects of education, LC8-6691, Medicine
Abstract

Purpose: Communication skills are an essential instrument for building a sustainable patient-doctor-relationship for future doctors. They are learnable and teachable. The learning should be facilitated with the help of a longitudinal curriculum, which is planned at Leipzig University.Project: At the Medical Faculty of Leipzig University, the Longitudinal Communication Curriculum is established since 2016/17. Up to now, the curriculum consists of four parts in which students repeatedly practise their communication skills in curricular and extracurricular courses. Several formats help to teach an integrated learning of communication and physical examination skills. Assessment of communication skills is also performed. Curricular implementation is accompanied by concomitant evaluation.Results: Three parts of the curriculum already have taken place. Students report an increase in communication skills. Students rate the units as instructive and helpful. The assessment of communication skills occurs in two clinical practical examinations (OSCEs). Together with summative assessment a formative feedback was implemented. Students judge this practice as highly positive.Discussion: The curriculum is part of undergraduate medical education in Leipzig. It would be beneficial to add another simulated patient encounter, as well as interprofessional units. Student questionnaires will be evaluated and results will help to develop the curriculum.Conclusion: Consolidation of the curriculum accompanied by evaluation and adaption of content can help to assure the quality of the curriculum. Additional professions and study units shall be integrated in the Longitudinal Communication Curriculum in the future.

Published
2021
Full Text
View/download PDF

10. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

Author

Younossi, Zobair M, AlQahtani, Saleh A, Alswat, Khalid, Yilmaz, Yusuf, Keklikkiran, Caglayan, Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Fan, Jian-Gao, Zheng, Ming-Hua, El-Kassas, Mohamed, Castera, Laurent, Liu, Chun-Jen, Wong, Vincent Wai-Sun, Zelber-Sagi, Shira, Allen, Alina M, Lam, Brian, Treeprasertsuk, Sombat, Hameed, Saeed, Takahashi, Hirokazu, Kawaguchi, Takumi, Schattenberg, Jörn M, Duseja, Ajay, Newsome, Phil, Francque, Sven, Spearman, C Wendy, Fernández, Marlen I Castellanos, Burra, Patrizia, Roberts, Stuart K, Chan, Wah-Kheong, Arrese, Marco, Silva, Marcelo, Rinella, Mary, Singal, Ashwani K, Gordon, Stuart, Fuchs, Michael, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Eskridge, Wayne, Kautz, Achim, Ong, Janus P, Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Yu, Ming-Lung, Gerber, Lynn, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Carrieri, Patrizia, Lazarus, Jeffrey V, and Council, the Global NASH

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis, Health Services, Clinical Research, Prevention, Good Health and Well Being, Global NASH Council, MASH, MASLD, SLD, communication, discrimination, fatty liver, metabolic, patient-reported outcomes, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsPatients with fatty liver disease may experience stigma from the disease or comorbidities. In this cross-sectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and healthcare providers.MethodsMembers of the Global NASH Council created two surveys about experiences/attitudes toward NAFLD and related diagnostic terms: a 68-item patient and a 41-item provider survey.ResultsSurveys were completed by 1,976 patients with NAFLD across 23 countries (51% Middle East/North Africa [MENA], 19% Europe, 17% USA, 8% Southeast Asia, 5% South Asia) and 825 healthcare providers (67% gastroenterologists/hepatologists) across 25 countries (39% MENA, 28% Southeast Asia, 22% USA, 6% South Asia, 3% Europe). Of all patients, 48% ever disclosed having NAFLD/NASH to family/friends; the most commonly used term was "fatty liver" (88% at least sometimes); "metabolic disease" or "MAFLD" were rarely used (never by >84%). Regarding various perceptions of diagnostic terms by patients, there were no substantial differences between "NAFLD", "fatty liver disease (FLD)", "NASH", or "MAFLD". The most popular response was being neither comfortable nor uncomfortable with either term (56%-71%), with slightly greater discomfort with "FLD" among the US and South Asian patients (47-52% uncomfortable). Although 26% of patients reported stigma related to overweight/obesity, only 8% reported a history of stigmatization or discrimination due to NAFLD. Among providers, 38% believed that the term "fatty" was stigmatizing, while 34% believed that "nonalcoholic" was stigmatizing, more commonly in MENA (43%); 42% providers (gastroenterologists/hepatologists 45% vs. 37% other specialties, p = 0.03) believed that the name change to metabolic dysfunction-associated steatotic liver disease (or MASLD) might reduce stigma. Regarding the new nomenclature, the percentage of providers reporting "steatotic liver disease" as stigmatizing was low (14%).ConclusionsThe perception of NAFLD stigma varies among patients, providers, geographic locations and sub-specialties.Impact and implicationsOver the past decades, efforts have been made to change the nomenclature of nonalcoholic fatty liver disease (NAFLD) to better align with its underlying pathogenetic pathways and remove any potential stigma associated with the name. Given the paucity of data related to stigma in NAFLD, we undertook this global comprehensive survey to assess stigma in NAFLD among patients and providers from around the world. We found there is a disconnect between physicians and patients related to stigma and related nomenclature. With this knowledge, educational programs can be developed to better target stigma in NAFLD among all stakeholders and to provide a better opportunity for the new nomenclature to address the issues of stigma.

Published
2023

13. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Author

Fuchs, Michael, Jacob, Anne Sophie, Kaul, Helen, Kobe, Carsten, Kuhnert, Georg, Pabst, Thomas, Greil, Richard, Bröckelmann, Paul J., Topp, Max S., Just, Marianne, Hertenstein, Bernd, Soekler, Martin, Vogelhuber, Martin, Zijlstra, Josée M., Keller, Ulrich Bernd, Krause, Stefan W., Dührsen, Ulrich, Meissner, Julia, Viardot, Andreas, Eich, Hans-Theodor, Baues, Christian, Diehl, Volker, Rosenwald, Andreas, Buehnen, Ina, von Tresckow, Bastian, Dietlein, Markus, Borchmann, Peter, Engert, Andreas, and Eichenauer, Dennis A.

Published
2024
Full Text
View/download PDF

15. THU-453 Stigma in NAFLD and NASH: a global survey of patients and providers

Author

Younossi, Zobair, Yılmaz, Yusuf, Fan, Jian-Gao, Wong, Vincent Wai-Sun, Kassas, Mohamed El, Zelber-Sagi, Shira, Allen, Alina, Rinella, Mary, Singal, Ashwani, Gordon, Stuart C, Fuchs, Michael, Eskridge, Wayne, Alkhouri, Naim, Alswat, Khalid, Takahashi, Hirokazu, Kawaguchi, Takumi, Ranagan, Jane, Zheng, Ming-Hua, Duseja, Ajay Kumar, Burra, Patrizia, Patrizia, Carrieri, Arrese, Marco, Kautz, Achim, Ong, Janus, Castera, Laurent, Francque, Sven, Kugelmas, Marcelo, Eguchi, Yuichiro, Treeprasertsuk, Sombat, Fernández, Marlen Ivon Castellanos, Gomez, Manuel Romero, Newsome, Philip N, Cusi, Kenneth, Loomba, Rohit, Schattenberg, Jörn, Yu, Ming-Lung, Diago, Moises, Gerber, Lynn, Lam, Brian, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Alqahtani, Saleh, and Lazarus, Jeffrey

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Published
2023

17. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Author

Borchmann, Peter, Ferdinandus, Justin, Schneider, Gundolf, Moccia, Alden, Greil, Richard, Hertzberg, Mark, Schaub, Valdete, Hüttmann, Andreas, Keil, Felix, Dierlamm, Judith, Hänel, Mathias, Novak, Urban, Meissner, Julia, Zimmermann, Andreas, Mathas, Stephan, Zijlstra, Josée M, Fosså, Alexander, Viardot, Andreas, Hertenstein, Bernd, Martin, Sonja, Giri, Pratyush, Scholl, Sebastian, Topp, Max S, Jung, Wolfram, Vucinic, Vladan, Beck, Hans-Joachim, Kerkhoff, Andrea, Unger, Benjamin, Rank, Andreas, Schroers, Roland, zum Büschenfelde, Christian Meyer, de Wit, Maike, Trautmann-Grill, Karolin, Kamper, Peter, Molin, Daniel, Kreissl, Stefanie, Kaul, Helen, von Tresckow, Bastian, Borchmann, Sven, Behringer, Karolin, Fuchs, Michael, Rosenwald, Andreas, Klapper, Wolfram, Eich, Hans-Theodor, Baues, Christian, Zomas, Athanasios, Hallek, Michael, Dietlein, Markus, Kobe, Carsten, and Diehl, Volker

Published
2024
Full Text
View/download PDF

19. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

Author

Younossi, Zobair M., AlQahtani, Saleh A., Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Yilmaz, Yusuf, Keklikkiran, Caglayan, Alswat, Khalid, Yu, Ming-Lung, Liu, Chun-Jen, Fan, Jian-Gao, Zheng, Ming-Hua, Burra, Patrizia, Francque, Sven M., Castera, Laurent, Schattenberg, Jörn M., Newsome, Philip N., Allen, Alina M., El-Kassas, Mohamed, Treeprasertsuk, Sombat, Hameed, Saeed, Wai-Sun Wong, Vincent, Zelber-Sagi, Shira, Takahashi, Hirokazu, Kawaguchi, Takumi, Castellanos Fernández, Marlen I., Duseja, Ajay, Arrese, Marco, Rinella, Mary, Singal, Ashwani K., Gordon, Stuart C., Fuchs, Michael, Eskridge, Wayne, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Kautz, Achim, Ong, Janus P., Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Gerber, Lynn, Lam, Brian, Fornaresio, Lisa, Nader, Fatema, Spearman, C. Wendy, Roberts, Stuart K., Chan, Wah-Kheong, Silva, Marcelo, Racila, Andrei, Golabi, Pegah, Ananchuensook, Prooksa, Henry, Linda, Stepanova, Maria, Carrieri, Patrizia, and Lazarus, Jeffrey V.

Published
2024
Full Text
View/download PDF

21. Answer to the Letter to the Editor of Tugba Ozudogru Celik concerning “Association between posterior tibial slope and anatomic spinopelvic parameters: a retrospective cross-sectional study” by Caffard T, et al. (Eur Spine J. 2023; doi: 10.1007/s00586-023-07830-1)

Author

Caffard, Thomas, Awan Malik, Hassan, Lutz, Bernd, Dobrindt, Oliver, Dornacher, Daniel, Faschingbauer, Martin, Strube, Patrick, Reichel, Heiko, Fuchs, Michael, and Zippelius, Timo

Published
2024
Full Text
View/download PDF

24. Author Correction: Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

Author

Sigmund, Anna M., Winkler, Markus, Engelmayer, Sophia, Kugelmann, Daniela, Egu, Desalegn T., Steinert, Letyfee S., Fuchs, Michael, Hiermaier, Matthias, Radeva, Mariya Y., Bayerbach, Franziska C., Butz, Elisabeth, Kotschi, Stefan, Hudemann, Christoph, Hertl, Michael, Yeruva, Sunil, Schmidt, Enno, Yazdi, Amir S., Ghoreschi, Kamran, Vielmuth, Franziska, and Waschke, Jens

Published
2023
Full Text
View/download PDF

25. Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

Author

Sigmund, Anna M., Winkler, Markus, Engelmayer, Sophia, Kugelmann, Daniela, Egu, Desalegn T., Steinert, Letyfee S., Fuchs, Michael, Hiermair, Matthias, Radeva, Mariya Y., Bayerbach, Franziska C., Butz, Elisabeth, Kotschi, Stefan, Hudemann, Christoph, Hertl, Michael, Yeruva, Sunil, Schmidt, Enno, Yazdi, Amir S., Ghoreschi, Kamran, Vielmuth, Franziska, and Waschke, Jens

Published
2023
Full Text
View/download PDF

26. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States.

Author

Kim, Nicole, Rozenberg-Ben-Dror, Karine, Jacob, David, Rich, Nicole, Singal, Amit, Aby, Elizabeth, Yang, Ju, Nguyen, Veronica, Pillai, Anjana, Fuchs, Michael, Moon, Andrew, Shroff, Hersh, Agarwal, Parul, Perumalswami, Ponni, Chandna, Shaun, Zhou, Kali, Patel, Yuval, Latt, Nyan, Wong, Robert, Duarte-Rojo, Andres, Lindenmeyer, Christina, Frenette, Catherine, Ge, Jin, Mehta, Neil, Yao, Francis, Benhammou, Jihane, Bloom, Patricia, Leise, Michael, Kim, Hyun-Seok, Levy, Cynthia, Barnard, Abbey, Khalili, Mandana, and Ioannou, George

Subjects
Computed Tomography, Liver Cancer, Magnetic Resonance Imaging, Screening, Ultrasound, Attitude of Health Personnel, Carcinoma, Hepatocellular, Diagnostic Tests, Routine, Early Detection of Cancer, Humans, Liver Cirrhosis, Liver Neoplasms, Ultrasonography, United States, alpha-Fetoproteins
Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) surveillance rates are suboptimal in clinical practice. We aimed to elicit providers opinions on the following aspects of HCC surveillance: preferred strategies, barriers and facilitators, and the impact of a patients HCC risk on the choice of surveillance modality. METHODS: We conducted a web-based survey among gastroenterology and hepatology providers (40% faculty physicians, 21% advanced practice providers, 39% fellow-trainees) from 26 US medical centers in 17 states. RESULTS: Of 654 eligible providers, 305 (47%) completed the survey. Nearly all (98.4%) of the providers endorsed semi-annual HCC surveillance in patients with cirrhosis, with 84.2% recommending ultrasound ± alpha fetoprotein (AFP) and 15.4% recommending computed tomography (CT) or magnetic resonance imaging (MRI). Barriers to surveillance included limited HCC treatment options, screening test effectiveness to reduce mortality, access to transportation, and high out-of-pocket costs. Facilitators of surveillance included professional society guidelines. Most providers (72.1%) would perform surveillance even if HCC risk was low (≤0.5% per year), while 98.7% would perform surveillance if HCC risk was ≥1% per year. As a patients HCC risk increased from 1% to 3% to 5% per year, providers reported they would be less likely to order ultrasound ± AFP (83.6% to 68.9% to 57.4%; P < .001) and more likely to order CT or MRI ± AFP (3.9% to 26.2% to 36.1%; P < .001). CONCLUSIONS: Providers recommend HCC surveillance even when HCC risk is much lower than the threshold suggested by professional societies. Many appear receptive to risk-based HCC surveillance strategies that depend on patients estimated HCC risk, instead of our current one-size-fits all strategy.

Published
2022

30. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

Author

Younossi, Zobair M., Alqahtani, Saleh A., Alswat, Khalid, Yilmaz, Yusuf, Keklikkiran, Caglayan, Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Fan, Jian-Gao, Zheng, Ming-Hua, El-Kassas, Mohamed, Castera, Laurent, Liu, Chun-Jen, Wai-Sun Wong, Vincent, Zelber-Sagi, Shira, Allen, Alina M., Lam, Brian, Treeprasertsuk, Sombat, Hameed, Saeed, Takahashi, Hirokazu, Kawaguchi, Takumi, Schattenberg, Jörn M., Duseja, Ajay, Newsome, Phil N., Francque, Sven, Spearman, C. Wendy, Castellanos Fernández, Marlen I., Burra, Patrizia, Roberts, Stuart K., Chan, Wah-Kheong, Arrese, Marco, Silva, Marcelo, Rinella, Mary, Singal, Ashwani K., Gordon, Stuart, Fuchs, Michael, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Eskridge, Wayne, Kautz, Achim, Ong, Janus P., Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Yu, Ming-Lung, Gerber, Lynn, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Carrieri, Patrizia, and Lazarus, Jeffrey V.

Published
2024
Full Text
View/download PDF

31. EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis

Author

Egu, Desalegn Tadesse, Schmitt, Thomas, Ernst, Nancy, Ludwig, Ralf Joachim, Fuchs, Michael, Hiermaier, Matthias, Moztarzadeh, Sina, Morón, Carla Sebastià, Schmidt, Enno, Beyersdorfer, Vivien, Spindler, Volker, Steinert, Letyfee Sarah, Vielmuth, Franziska, Sigmund, Anna Magdalena, and Waschke, Jens

Published
2024
Full Text
View/download PDF

33. Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group

Author

Rosenbrock, Johannes, Kaul, Helen, Oertel, Michael, Celik, Eren, Linde, Philipp, Fan, Jiaqi, Eichenauer, Dennis A., Bröckelmann, Paul J., von Tresckow, Bastian, Kobe, Carsten, Dietlein, Markus, Fuchs, Michael, Borchmann, Peter, Eich, Hans Theodor, and Baues, Christian

Published
2024
Full Text
View/download PDF

37. A global research priority agenda to advance public health responses to fatty liver disease

Author

Lazarus, Jeffrey V., Mark, Henry E., Allen, Alina M., Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A., Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N., Burra, Patrizia, Castro-Narro, Graciela E., Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M., Hagström, Hannes, Huang, Terry T-K., Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J., Krag, Aleksander, Miller, Veronica, Newsome, Philip N., Rinella, Mary E., Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C. Wendy, Tsochatzis, Emmanuel A., Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M., Wong, Vincent Wai-Sun, Younossi, Zobair M., Aberg, Fredrik, Adams, Leon, Al-Naamani, Khalid, Albadawy, Reda M., Alexa, Zinaida, Allison, Michael, Alnaser, Faisal A., Alswat, Khalid, Alvares-da-Silva, Mario Reis, Alvaro, Domenico, Alves-Bezerra, Michele, Andrade, Raul J., Anstee, Quentin M., Awuku, Yaw Asante, Baatarkhuu, Oidov, Baffy, Gyorgy, Bakieva, Shokhista, Bansal, Meena B., Barouki, Robert, Batterham, Rachel L., Behling, Cynthia, Belfort-DeAguiar, Renata, Berzigotti, Annalisa, Betel, Michael, Bianco, Cristiana, Bosi, Emanuele, Boursier, Jerome, Brunt, Elizabeth M., Bugianesi, Elisabetta, Byrne, Christopher J., Cabrera Cabrejos, Maria Cecilia, Caldwell, Stephen, Carr, Rotonya, Castellanos Fernández, Marlen Ivón, Castera, Laurent, Castillo-López, Maria Gabriela, Caussy, Cyrielle, Cerda-Reyes, Eira, Ceriello, Antonio, Chan, Wah- Kheong, Chang, Yoosoo, Charatcharoenwitthaya, Phunchai, Chavez-Tapia, Norberto, Chung, Raymond T., Colombo, Massimo, Coppell, Kirsten, Cotrim, Helma P., Craxi, Antonio, Crespo, Javier, Dassanayake, Anuradha, Davidson, Nicholas O., De Knegt, Robert, de Ledinghen, Victor, Demir, Münevver, Desalegn, Hailemichael, Diago, Moises, Dillon, John F., Dimmig, Bruce, Dirac, M. Ashworth, Dirchwolf, Melisa, Dufour, Jean-François, Dvorak, Karel, Ekstedt, Mattias, El-Kassas, Mohamed, Elsanousi, Osama M., Elsharkawy, Ahmed M., Elwakil, Reda, Eskridge, Wayne, Eslam, Mohammed, Esmat, Gamal, Fan, Jian- Gao, Ferraz, Maria Lucia, Flisiak, Robert, Fortin, Davide, Fouad, Yasser, Freidman, Scott L., Fuchs, Michael, Gadano, Adrian, Gastaldelli, Amalia, Geerts, Anja, Geier, Andreas, George, Jacob, Gerber, Lynn H., Ghazinyan, Hasmik, Gheorghe, Liana, Kile, Denise Giangola, Girala, Marcos, Boon Bee, George Goh, Goossens, Nicolas, Graupera, Isabel, Grønbæk, Henning, Hamid, Saeed, Hebditch, Vanessa, Henry, Zachary, Hickman, Ingrid J., Hobbs, L. Ansley, Hocking, Samantha L., Hofmann, Wolf Peter, Idilman, Ramazan, Iruzubieta, Paula, Isaacs, Scott, Isakov, Vasily A., Ismail, Mona H., Jamal, Mohammad H., Jarvis, Helen, Jepsen, Peter, Jornayvaz, François, Sudhamshu, K.C., Kakizaki, Satoru, Karpen, Saul, Kawaguchi, Takumi, Keating, Shelley E., Khader, Yousef, Kim, Seung Up, Kim, Won, Kleiner, David E., Koek, Ger, Joseph Komas, Narcisse Patrice, Kondili, Loreta A., Koot, Bart G., Korenjak, Marko, Kotsiliti, Eleni, Koulla, Yiannoula, Kugelmas, Carina, Kugelmas, Marcelo, Labidi, Asma, Lange, Naomi F., Lavine, Joel E., Lazo, Mariana, Leite, Nathalie, Lin, Han-Chieh, Lkhagvaa, Undram, Long, Michelle T., Lopez-Jaramillo, Patricio, Lozano, Adelina, Macedo, Maria Paula, Malekzadeh, Reza, Marchesini, Giulio, Marciano, Sebastian, Martinez, Kim, Martínez Vázquez, Sophia E., Mateva, Lyudmila, Mato, José M., Nlombi, Charles Mbendi, McCary, Alexis Gorden, McIntyre, Jeff, McKee, Martin, Mendive, Juan M., Mikolasevic, Ivana, Miller, Pamela S., Milovanovic, Tamara, Milton, Terri, Moreno-Alcantar, Rosalba, Morgan, Timothy R., Motala, Ayesha, Muris, Jean, Musso, Carla, Nava-González, Edna J., Negro, Francesco, Nersesov, Alexander V., Neuschwander-Tetri, Brent A., Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Ocama, Ponsiano, Ong, Janus P., Ong-Go, Arlinking, Onyekwere, Charles, Padilla, Martin, Pais, Raluca, Pan, Calvin, Panduro, Arturo, Panigrahi, Manas K., Papatheodoridis, Georgios, Paruk, Imran, Patel, Keyur, Gonçalves, Carlos Penha, Figueroa, Marlene Pérez, Pérez-Escobar, Juanita, Pericàs, Juan M., Perseghin, Gianluca, Pessoa, Mário Guimarães, Petta, Salvatore, Marques Souza de Oliveira, Claudia Pinto, Prabhakaran, Dorairaj, Pyrsopoulous, Nikolaos, Rabiee, Atoosa, Ramji, Alnoor, Ratziu, Vlad, Ravendhran, Natarajan, Ray, Katrina, Roden, Michael, Romeo, Stefano, Romero-Gómez, Manuel, Rotman, Yaron, Rouabhia, Samir, Rowe, Ian A., Sadirova, Shakhlo, Alkhatry, Maryam Salem, Salupere, Riina, Satapathy, Sanjaya K., Schwimmer, Jeffrey B., Sebastiani, Giada, Seim, Lynn, Seki, Yosuke, Serme, Abdel Karim, Shapiro, David, Sharvadze, Lali, Shaw, Jonathan E., Shawa, Isaac Thom, Shenoy, Thrivikrama, Shibolet, Oren, Shimakawa, Yusuke, Shubrook, Jay H., Singh, Shivaram Prasad, Sinkala, Edford, Skladany, Lubomir, Skrypnyk, Igor, Song, Myeong Jun, Sookoian, Silvia, Sridharan, Kannan, Stefan, Norbert, Stine, Jonathan G., Stratakis, Nikolaos, Sheriff, Dhastagir Sultan, Sundaram, Shikha S., Svegliati-Baroni, Gianluca, Swain, Mark G., Tacke, Frank, Taheri, Shahrad, Tan, Soek-Siam, Tapper, Elliot B., Targher, Giovanni, Tcaciuc, Eugen, Thiele, Maja, Tiniakos, Dina, Tolmane, Ieva, Torre, Aldo, Torres, Esther A., Treeprasertsuk, Sombat, Trenell, Michael, Turcan, Svetlana, Turcanu, Adela, Valantinas, Jonas, van Kleef, Laurens A., Velarde Ruiz Velasco, Jose Antonio, Vesterhus, Mette, Vilar-Gomez, Eduardo, Waked, Imam, Wattacheril, Julia, Wedemeyer, Heiner, Wilkins, Fonda, Willemse, José, Wong, Robert J., Yilmaz, Yusuf, Yki-Järvinen, Hannele, Yu, Ming-Lung, Yumuk, Volkan, Zeybel, Müjdat, Zheng, Kenneth I., Zheng, Ming-Hua, and Huang, Terry T.-K.

Published
2023
Full Text
View/download PDF

45. Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

Author

Jacob, Anne Sophie, Kaul, Helen, Fuchs, Michael, Gillessen, Sarah, Kreissl, Stefanie, Pluetschow, Annette, Momotow, Jesko, Schaub, Valdete, Huettmann, Andreas, Haenel, Mathias, Zimmermann, Andreas, Dierlamm, Judith, Meissner, Julia, Mathas, Stephan, Martin, Sonja, Engert, Andreas, Hallek, Michael, Borchmann, Peter, and Lehmann, Clara

Published
2022
Full Text
View/download PDF

47. Serum and urinary metabolomics and outcomes in cirrhosis

Author

Bajaj, Jasmohan S, Fan, Sili, Thacker, Leroy R, Fagan, Andrew, Gavis, Edith, White, Melanie B, Heuman, Douglas M, Fuchs, Michael, and Fiehn, Oliver

Subjects
Medical Biochemistry and Metabolomics, Analytical Chemistry, Biomedical and Clinical Sciences, Chemical Sciences, Liver Disease, Digestive Diseases, Transplantation, Good Health and Well Being, Adult, Aged, Biomarkers, Female, Hepatic Encephalopathy, Hospitalization, Humans, Liver Cirrhosis, Liver Transplantation, Male, Metabolomics, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, General Science & Technology
Abstract

BackgroundCirrhosis can alter several metabolic pathways. Metabolomics could prognosticate outcomes like hepatic encephalopathy (HE), transplant, hospitalization and death.AimDetermine changes in serum and urine metabolomics in cirrhotics who develop outcomes.MethodsCirrhotic outpatients underwent data, serum/urine collection and were followed for 90 days. Demographics, cirrhosis details and medications were collected. Metabolomics was performed on urine/serum using GC/MS with subsequent bioinformatics analyses (ChemRICH, MetaMAPP and PLS-DA). Logistic regression adjusting for covariates (demographics, alcohol etiology, prior HE, PPI, SBP prophylaxis, rifaximin/lactulose) were performed and ROC curves comparing MELD to adjusted serum & urine metabolites were created.Results211 patients gave serum, of which 64 were hospitalized, 19 developed HE, 13 were transplanted and 11 died. 164 patients gave urine of which 56 were hospitalized, 18 developed HE, 12 were transplanted and 11 died. Metabolomics: Saturated fatty acids, amino acids and bioenergetics-related metabolites differentiated patients with/without outcomes. After regression, 232, 228, 284 and 229 serum metabolites were significant for hospitalization, HE, death and transplant. In urine 290, 284, 227 & 285 metabolites were significant for hospitalization, HE, death and transplant respectively. AUC was higher for serum metabolites vs MELD for HE (0.85 vs.0.76), death (0.99 vs.0.88), transplant (0.975 vs.0.94) and hospitalizations (0.84 vs.0.83). Similarly, urinary metabolite AUC was also higher than MELD for HE (0.87 vs.0.72), death (0.92 vs 0.86), transplant (0.99 vs.0.90) and hospitalizations (0.89 vs.0.84).ConclusionsIn this exploratory study, serum and metabolites focused on lipid, bioenergetics and amino acid metabolism are altered in cirrhotics who develop negative outcomes.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results